<?xml version="1.0" encoding="UTF-8"?>
<modsCollection xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
  <mods>
    <titleInfo>
      <title>Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis</title>
    </titleInfo>
    <name type="personnal">
      <namePart type="family">Bastard</namePart>
      <namePart type="given">M.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Fall</namePart>
      <namePart type="given">M. B. K.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Lanièce</namePart>
      <namePart type="given">I.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Taverne</namePart>
      <namePart type="given">Bernard</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Desclaux</namePart>
      <namePart type="given">Alice</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Ecochard</namePart>
      <namePart type="given">R.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Sow</namePart>
      <namePart type="given">P. S.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Delaporte</namePart>
      <namePart type="given">Eric</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Etard</namePart>
      <namePart type="given">Jean-François</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <typeOfResource>text</typeOfResource>
    <genre authority="local">journalArticle</genre>
    <language>
      <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
    </language>
    <physicalDescription>
      <internetMediaType>text/pdf</internetMediaType>
      <digitalOrigin>born digital</digitalOrigin>
      <reformattingQuality>access</reformattingQuality>
    </physicalDescription>
    <abstract>Background: Adherence is one of the main predictors of antiretroviral treatment success. A governmental initiative was launched in 1998 for HIV-infected patients in Senegal to provide access to highly active antiretroviral therapy. Methods: Between August 1998 and April 2002, 404 adult patients were enrolled. Adherence measurements, defined as pills taken/pills prescribed, were assessed between November 1999 and April 2009 using a pill count along with a questionnaire for 330 patients. Predictors of adherence were explored through a random-intercept Tobit model and a latent class analysis (LCA) was performed to identify adherence trajectories. We also performed a survival analysis taking into account gender and latent adherence classes. Results: Median treatment duration was 91 months (interquartile range, 84-101). On average, adherence declined by 7% every year, was 30% lower for patients taking indinavir, and 12% higher for those receiving cotrimoxazole prophylaxis. Based on the predicted probability of having an adherence &gt;= 95%, LCA revealed 3 adherence behaviors and a better adherence for women. A quarter of patients had a high adherence trajectory over time and half had an intermediate one. Male gender and low adherence behavior over time were independently associated with a higher mortality rate. Conclusions: This study shows that an overall good adherence can be obtained in the long term in Senegal. LCA suggests a better adherence for women and points out a large subsample of patients with intermediate level of adherence behavior who are at risk for developing resistance to antiretroviral drugs. This study warrants further research into gender issues.</abstract>
    <targetAudience authority="marctarget">specialized</targetAudience>
    <subject>
      <topic>antiretroviral therapy</topic>
      <topic>adherence</topic>
      <topic>latent class analysis</topic>
      <topic>mixed model</topic>
      <topic>women</topic>
      <topic>Senegal</topic>
    </subject>
    <classification authority="local">052</classification>
    <relatedItem type="host">
      <titleInfo>
        <title>Jaids-Journal of Acquired Immune Deficiency Syndromes</title>
      </titleInfo>
      <part>
        <detail type="volume">
          <number>57</number>
        </detail>
        <detail type="volume">
          <number>1</number>
        </detail>
        <extent unit="pages">
          <list> 55-61</list>
        </extent>
      </part>
      <originInfo>
        <dateIssued>2011</dateIssued>
      </originInfo>
      <identifier type="issn">1525-4135</identifier>
    </relatedItem>
    <identifier type="uri">https://www.documentation.ird.fr/hor/fdi:010053486</identifier>
    <identifier type="doi">10.1097/QAI.0b013e318211b43b</identifier>
    <identifier type="issn">1525-4135</identifier>
    <location>
      <shelfLocator>[F B010053486]</shelfLocator>
      <url usage="primary display" access="object in context">https://www.documentation.ird.fr/hor/fdi:010053486</url>
      <url access="row object">https://www.documentation.ird.fr/intranet/publi/2011/05/010053486.pdf</url>
    </location>
    <accessCondition type="restriction access" displayLabel="Accès réservé">Accès réservé (Intranet de l'IRD)</accessCondition>
    <recordInfo>
      <recordContentSource>IRD - Base Horizon / Pleins textes</recordContentSource>
      <recordCreationDate encoding="w3cdtf">2011-05-31</recordCreationDate>
      <recordChangeDate encoding="w3cdtf">2017-08-23</recordChangeDate>
      <recordIdentifier>fdi:010053486</recordIdentifier>
      <languageOfCataloging>
        <languageTerm authority="iso639-2b">fre</languageTerm>
      </languageOfCataloging>
    </recordInfo>
  </mods>
</modsCollection>
